drugset / Trial / NCT06894745
PET [89Zr]DFO-starPEG in Solid Tumors
Phase 1
Recruiting
13 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collabProLynx LLC · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.
Timeline
- Start
- 2025-06-02
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89-zr-dfo-star polyethylene glycol | Diagnostic / imaging agent | 1 unknown | Intravenous |
| Subject | 89-zr-dfo-star polyethylene glycol | Diagnostic / imaging agent | 2 unknown | Intravenous |